Get the app
NSE › Healthcare

Dishman Carbogen Amcis Limited (DCAL)

NSE · Healthcare · Biotechnology

₹149.83-0.89%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
₹68 cr
Revenue YoY
-90.4%
Net profit
₹-6 cr
Profit YoY
-124.7%
Net margin
-8.5%

Key statistics

Market cap
₹2,349 cr
P/E
146.9
Forward P/E
0.3
P/B
0.40
Book value
₹426.90
EPS (TTM)
₹1.02
52-week high
₹303.00
52-week low
₹128.50
50-day MA
₹168.94
200-day MA
₹182.20
Beta
0.65

Analyst view

with an average price target of ₹165.00.

Shareholding

Promoters
59.32%
Institutions
2.71%

Largest named holders

HolderStake
Mukul Mahavir Agrawal5.50%
Massachusetts Institute of Technology2.28%
Hbm Healthcare Investments (Cayman) Ltd2.19%
HSBC Mutual Fund - HSBC Flexi Cap Fund1.41%

Recent filings & reports

DocumentDate
Annual report FY2026
DISHMAN CARBOGEN AMCIS LIMITED - ANNUAL REPORT FY26 SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹29,319 million (₹2,931.9 crores), up 8.1% Y
2026-09-05
Q1 FY27 earnings call
DISHMAN CARBOGEN AMCIS LIMITED - Q1 FY27 SUMMARY HEADLINE NUMBERS • Revenue for Q1 FY27 (quarter ending June 30, 2026): INR 6,776 million vs INR 7,0
2026-08-21
Investor presentation · Q1 FY27
DISHMAN CARBOGEN AMCIS LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Net Revenue Q1 FY27: ₹6,776 million, down 4.3% YoY from ₹7,081 million in Q1 FY2
2026-08-17
Quarterly results · Q1 FY27
DISHMAN CARBOGEN AMCIS LIMITED – Q1 FY2027 FINANCIAL SUMMARY HEADLINE NUMBERS • Consolidated Revenue (Q1 FY2027): ₹677.64 crores vs ₹708.05 crores (
2026-08-14
Quarterly results · Q4 FY26
DISHMAN CARBOGEN AMCIS LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Total Revenue (Consolidated, FY2026): INR 2,931.90 crores (vs INR 2,711.50 cro
2026-06-22
Q4 FY26 earnings call
DISHMAN CARBOGEN AMCIS LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • Q4 FY26 Revenue: INR 851 crores (19% growth vs INR 716 crores in Q4 FY25) • Full
2026-05-25
Investor presentation
DISHMAN CARBOGEN AMCIS LIMITED – INVESTOR SUMMARY Q4 FY26 & FY26 (Year ended March 31, 2026) --- HEADLINE NUMBERS • FY26 Net Revenue: ₹29,319 mn (u
2026-05-20
Q3 FY26 earnings call
DISHMAN CARBOGEN AMCIS LIMITED – Q3 FY26 SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue: INR 720 crores vs INR 682 crores in Q3 FY25 (5.5% growth) • 9-M
2026-02-10

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dishman Carbogen Amcis Limited — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Data updated 2026-10-19.